These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 3925573)

  • 1. [Response to DDAVP in von Willebrand disease type II C].
    Batllé Fonrodona J; López Fernández MF; Martín González R; Fernández Villamor A; López Borrasca A; Lasierra Cirujeda J
    Sangre (Barc); 1985; 30(2):181-4. PubMed ID: 3925573
    [No Abstract]   [Full Text] [Related]  

  • 2. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ; Casanova R
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
    Blättler W; Jacky E; Müller M; Graf M
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1367-8. PubMed ID: 314661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of D-arginine vasopressin in von Willebrand's disease.
    Bala L; Boggio L; Green D
    Curr Hematol Rep; 2005 Jan; 4(1):1-2. PubMed ID: 15610653
    [No Abstract]   [Full Text] [Related]  

  • 6. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.
    Ruggeri ZM; Mannucci PM; Lombardi R; Federici AB; Zimmerman TS
    Blood; 1982 Jun; 59(6):1272-8. PubMed ID: 6805532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [DDAVP: alternative therapy in moderate pathology of Factor VIII/von Willebrand].
    Vicente V; Alberca I; Moraleda JM; López Borrasca A
    Sangre (Barc); 1983; 28(4):531-2. PubMed ID: 6606856
    [No Abstract]   [Full Text] [Related]  

  • 8. DDAVP in haemophilia and von Willebrand's disease.
    Lancet; 1983 Oct; 2(8353):774-5. PubMed ID: 6137606
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hemostatic effect of deamino-8-D-arginine vasopressin (DDAVP) in hemophilia A and von Willebrand's disease].
    Fukui H; Takase T
    Rinsho Ketsueki; 1985 Jul; 26(7):1069-79. PubMed ID: 3932720
    [No Abstract]   [Full Text] [Related]  

  • 11. No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's disease.
    Castaman G; Rodeghiero F
    Thromb Haemost; 1995 Mar; 73(3):551-2. PubMed ID: 7667843
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical application of new synthetic vasopressin 1-deamino-8-D-arginine vasopressin (DDAVP): hemostatic control of von Willebrand's disease (author's transl)].
    Kobayashi I; Takahashi H; Sanada M; Takahashi K; Hattori A; Ito M; Sakuragawa N; Shibata A; Shinada S; Tsukada T
    Rinsho Ketsueki; 1979 Apr; 20(4):364-71. PubMed ID: 312954
    [No Abstract]   [Full Text] [Related]  

  • 13. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild forms of von Willebrand disease: diagnosis and management.
    Federici AB
    Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of blood coagulation disorders with the vasopressin derivative DDAVP (Minirin)].
    Köhler M; Hellstern P; Vief B; Wenzel E
    ZFA (Stuttgart); 1981 May; 57(15):1132-5. PubMed ID: 6973250
    [No Abstract]   [Full Text] [Related]  

  • 16. [Multimeric composition of factor VIII-related protein following DDAVP infusion in normal subjects and patients with hemophilia A and von Willebrand's disease].
    Takase T; Nishino M; Yasui M; Shima M; Yoshikawa N; Fukui H
    Nihon Ketsueki Gakkai Zasshi; 1985 Nov; 48(7):1571-8. PubMed ID: 3937410
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patients.
    Mariana G; Ciavarella N; Mazzucconi MG; Antoncecchi S; Solinas S; Ranieri P; Pettini P; Agrestini F; Mandelli F
    Clin Lab Haematol; 1984; 6(3):229-38. PubMed ID: 6440729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the management of von Willebrand disease.
    Federici AB
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
    [No Abstract]   [Full Text] [Related]  

  • 19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDAVP in von Willebrand's disease: repeated administration and the behaviour of the bleeding time.
    Theiss W; Schmidt G
    Thromb Res; 1978 Dec; 13(6):1119-23. PubMed ID: 311959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.